PTC Therapeutics, Inc. (PTCT)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 33.57 |
| Open | 34.08 |
| Bid | 33.97 x 100 |
| Ask | 34.13 x 200 |
| Day's range | 33.62 - 34.56 |
| 52-week range | 17.53 - 42.14 |
| Volume | |
| Avg. volume | 906,679 |
| Market cap | 2.615B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.69 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 37.00 |
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, Aug. 8, at 4:30 p.m. EDT.
ZacksWill PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksPTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
© 2024 Yahoo. All rights reserved.